RARE Deadline: RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit Accessibility StatementSkip NavigationNEW YORK, March 25, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.So what: If you purchased Ultragenyx common stock ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ultragenyx (RARE) To Contact Him Directly To Discuss Their Options If you purchased or acquired Ultragenyx common stock between August 3, 2023, to December 26, 2025, and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- What’s Ha ...

SAN DIEGO--(BUSINESS WIRE)---- $RARE #Medicine--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025. Ultragenyx is a biopharmaceutical company focused on rare and ultrarare genetic disorders. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? Robbins L ...

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

RARE Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Ultragenyx Pharmaceutical Inc. Securities Lawsuit -- The Gross Law Firm Accessibility StatementSkip NavigationNEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment ...

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, all dates inclusive (the “Class Period”), have until Monday, April 6, 2026 to seek appointment as lead plaintiff of the Ultragenyx class action lawsuit. Captioned Bailey v. Ultragenyx Pharmaceutical Inc., No. 26-cv-01097 (N.D. Cal.), the Ultragenyx class action lawsuit charg ...

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased shares during the specified Class Period, alleging misrepresentation of clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx misrepresented the results of the ORBIT and COSMIC Phase 3 programs for setrusumab, a treatment for Osteogenesis Imperfecta [3]. - Investors were informed on December 29, 2025, that neither clinical trial met its primary endpoint, leading to a significant drop in the company's share value by over 42% in one trading day [3]. Group 2: Company Overview - Ultragenyx is a biopharmaceutical company based in Novato, California, focused on developing novel products for rare diseases [2]. - The company is involved in the acquisition and development of treatments aimed at addressing unmet medical needs in rare disease populations [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of their Phase III Orbit and Cosmic Studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that the defendants made overly positive statements about setrusumab's efficacy while concealing material adverse facts, leading to inflated stock prices for Ultragenyx [6].